Stephen P. Samuel

Stephen P. Samuel

Auto-generated profile, based on publicly available information

Stephen P. Samuel

California Academy of Sciences, San Francisco, 94118 CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2018 in Journal of Tropical Medicine
Verified
Journal Article
Open access
PDF file
TBTommaso Bulfone
Tommaso Bulfone
SSStephen P. Samuel
Stephen P. Samuel
PBPhilip E. Bickler
Philip E. Bickler
MLMatthew Lewin
Matthew Lewin
The World Health Organization (WHO) recently added snakebite envenoming to the priority list of Neglected Tropical Diseases (NTD). It is thought that ~75% of mortality following snakebite occurs outside the hospital setting, making the temporal gap between a bite and antivenom administration a major therapeutic challenge. Small molecule therapeutics (SMTs) have been proposed as potential prereferral treatments for snakebite to help address this gap. Herein, we discuss the characteristics, potential uses, and development of SMTs as potential treatments for snakebite envenomation. We focus on SMTs that are secretory phospholipase A2 (sPLA2) inhibitors with brief exploration of other potential drug targets on venom molecules.